Results

Regeneron Pharmaceuticals Inc.

10/25/2021 | Press release | Distributed by Public on 10/24/2021 23:01

Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex[...]